Trial · NCT01587703
Outcomes80
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 80
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD | Median of 1.38 months of drug exposure | All Treated Population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With AEs and SAEs-Part 1 BID | Median of 1.41 months of drug exposure | All Treated Population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With AEs and SAEs-Part 2 | Median of 1.41 months of drug exposure | All Treated Population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Dose Reductions or Delays-Part 1 QD | Median of 1.38 months of drug exposure | All Treated Population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Dose Reductions or Delays-Part 1 BID | Median of 1.41 months of drug exposure | All Treated Population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Dose Reductions or Delays-Part 2 | Median of 1.41 months of drug exposure | All Treated Population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Dose Reductions or Delays-Besylate Sub-study | Median of 1.87 months of drug exposure | All Treated Population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Withdrawn Due to Toxicities-Part 1 QD | Median of 1.38 months of drug exposure | All Treated Population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Withdrawn Due to Toxicities-Part 1 BID | Median of 1.41 months of drug exposure | All Treated Population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Withdrawn Due to Toxicities-Part 2 | Median of 1.41 months of drug exposure | All Treated Population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Withdrawn Due to Toxicities-Besylate Sub-study | Median of 1.87 months of drug exposure | All Treated Population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure | All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles). | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure | All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles). | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure | All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles). | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure | All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles). | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure | All Treated Population. Only those participants with data available at the specified time points were analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure | All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles). | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure | All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles). | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure | All Treated Population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Baseline (pre-dose Week1 Day1) and Weeks 5, 9, 17, 25, 33, 41, 49 and discharge/progression (disc/prog) | All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles). | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01587703/outcomes